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1500 words 
Abstract (150 words) 
Oxytocin causes myometrial contractions and prostaglandin release.  It is commonly used as an 
intervention for women in established labour with slow progress.  However recent large randomised 
trials of oxytocin for this indication have shown no difference in caesarean section rates associated 
with its use.  This may be due to inadequate doses of oxytocin and small randomised studies have 
suggested high dose oxytocin may indeed reduce caesarean delivery.  The results of a high quality 
large randomised trial of high versus low dose oxytocin for women with slow progress are keenly 
awaited. There is no evidence to support the concept of turning the oxytocin off once contractions 
have been established with the hormone although this certainly merits further investigation.  Recent 
evidence of contemporary labour patterns indicate that our whole concept of slow progress in labour 
is fundamentally flawed. 
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Background 
Oxytocin, is a hormone produced by the hypothalamus and secreted by the posterior pituitary which 
acts on oxytocin receptors causing myometrial contractions and prostaglandin release in the decidua.  
Oxytocin receptor antagonists (e.g. atosiban) can be used for preterm labour to inhibit uterine 
contractions.  
Oxytocin for poor labour progress 
Oxytocin may be used for women in established labour with slow progress in an attempt to increase 
the frequency and power of uterine contractions and therefore cervical dilatation.  A recent Cochrane 
review of 8 studies (1338 women) examined the effect of oxytocin use in low-risk women at term with 
slow progress in the active stage of labour. The review made two comparisons: firstly the use of 
intravenous oxytocin with either placebo or no treatment (3 trials, 138 women) and secondly the 
immediate use versus the delayed use (≥ one hour) of intravenous oxytocin (5 trials, 1200 women).  
For both comparisons there was no difference in caesarean delivery associated with oxytocin use for 
this indication.  The only notable difference in the groups was that early use versus delayed use of 
oxytocin was associated with a two hour reduction in the time to delivery but not as a result of 
increased caesarean deliveries. 
What dose of oxytocin is sufficient? 
Are we simply not using high enough doses of oxytocin to see a difference in the groups?  
A Cochrane review of 4 studies (644 women) comparing high dose (defined as starting dose and 
increment of ≥ 4 mU per minute) with low-dose regimens (defined as starting dose and an increment 
of < 4 mU per minute) of oxytocin found that high-dose regimens were associated with a reduction in 
the length of labour (mean difference 3.5 hours) and caesarean section rates (RR 0.62; 95% CI 0.44-
0.86) and an increase in vaginal delivery (RR 1.35; 95% CI 1.13-1.62) with no difference in uterine 
hyperstimulation or neonatal admission to a special care baby unit.  Reported neonatal outcomes 
were limited and only provide limited reassurance of the safety for babies of high dose oxytocin.  The 
HOLDS trial (planned sample size 1500 women) is a double blind RCT of standard dose oxytocin 
(2mU/min increasing every 30 minutes to a maximum 32mU/min) versus high dose regimen 
(4mU/min increasing every 30 minutes to a maximum of 64mU/min) which is currently recruiting and 
seeks to provide the definitive answer to the question (ISRCTN 99841044).  
Should we turn the oxytocin off once contractions are regular? 
Another plausible suggestions is that syntocinon could be used to initiate uterine contractions during 
active labour with slow progress but then be switched off.  This is examined in a recent meta-analysis 
by Saccone et al which planned to examine both women in established labour undergoing 
augmentation for slow progress and women undergoing induction of labour but all nine trials 
identified, only included trials of women undergoing induction of labour.  Perhaps surprisingly women 
in the intervention group which involved discontinuation of syntocinon once the active phase of 
labour was achieved, but reinstitution if slow progress (no cervical dilation in 2 hours) or inadequate 
uterine contractions (for ≥ 2 hours) versus continuation of oxytocin until delivery found lower rates of 
uterine hyperstimulation (6.2% versus 13%; RR 0.53, 95% CI 0.33–0.84) and caesarean section (9.3% 
versus 15%; RR 0.64, 95% CI 0.48–0.87) associated with the intervention. 
Is our definition of slow progress in labour wrong fundamentally? 
What is acceptable progress in the active phase or first stage of labour?  Secondly when does active 
labour start?   
The standard definitions used by NICE for active labour is ‘regular painful contractions and progressive 
cervical dilatation from 4 cm’ and for slow progress in active labour is cervical dilatation of less than 
2 cm in 4 hours for first labours.  This is largely based on work from 50 years ago on labour progress 
in a medicalised setting.  While the introduction of partograms is an important safety net to prevent 
the maternal and neonatal morbidity and mortality associated with obstructed labour, some have 
argued that the strict parameters used to define adequate progress in labour pathologise a normal 
physiological progress.  In 2010 Zhang et al re-examined labour patterns using contemporary labour 
data and found that progress from 4 to 6cm was much slower than previously described leading the 
American College of Obstetricians and Gynaecologists to recommend that active labour should not be 
diagnosed until 6cm dilatation if there are no fetal or maternal concerns.  Given that the leading 
reason for primary caesarean delivery in the US is slow labour progress this could have a dramatic 
effect on CS rates in the US. Zhang’s extensive work in this area, summarised succinctly in a narrative 
review by Karacam et al has shown us that labour progress is not linear, but rather occurs in a step-
wise fashion with fluctuating periods of “acceleration and quiescence”. 
Alternatives to oxytocin 
Titrated oral misoprostol, a prostaglandin analogue, widely used in reproductive health, has been 
researched as an alternative to oxytocin for slow labour progress.  A Cochrane review of two trials 
(581 women) with different misoprostol regimes (20mcg repeated hourly, 75mcg repeated four 
hourly) found inadequate maternal and neonatal adverse outcome reporting to determine safety of 
misoprostol for this indication.  It also found conflicting results where women in the lower dose group 
(20mcg) had a lower incidence of tachysystole than those in the oxytocin group and conversely women 
in the higher dose group (75mcg) had a higher incidence of hyperstimulation than those in the 
oxytocin group.  It concluded that there was insufficient evidence of the safety and efficacy of 
misoprostol to recommend its use for this indication. 
Conclusion 
Oxytocin used for slow labour progress has a modest effect on the duration of labour but not reduce 
caesarean section rates.  This finding could be explained by the testing of inadequate doses of oxytocin 
used in trials in this area.  The results of a large randomised trial of high versus low dose oxytocin are 
eagerly awaited.  The questions: can oxytocin be used to increase contractions for slow labour and 
then turned off; can oral misoprostol be used to augment labour, merit further research.  Research 
into contemporary labour patterns indicates that active labour starts at 6cm, not 4cm, implementing 
this change could result in a reduction in the diagnosis of slow labour, requirement for oxytocin 
augmentation and emergency caesarean sections for slow labour progress. 
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